Articles tagged "Co-stimulation"

2016 American Transplant Congress
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.
M. Tseng,¹ S. Ge,¹ R. Roberts,² C. Kuo,² J. Choi,¹ N. Nissen,¹ M. Chu,¹ I. Kim,¹ B. Shin,¹ M. Toyoda,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pediatrics & Immunology, UCLA, Los Angeles, CA.
Introduction: Monoclonal antibodies that disrupt CD40/CD40 ligand (CD40L) interactions are likely to have utility in human transplantation. However, the extent of the immunosuppressive effects of…
2016 American Transplant Congress
CTLA4 Negatively Regulates Donor-Reactive CXCR5+PD1+ T Follicular Helper Cell Responses Following Transplantation.
I. Badell,¹ D. Liu,¹ S. Suchard,² S. Nadler,² M. Ford.¹
¹Emory Transplant Center, Atlanta; ²Bristol-Myers Squibb, Princeton.
Costimulation blockade of the CD28 pathway in the form of CTLA4Ig is known to attenuate T cell dependent antibody responses. T follicular helper (Tfh) cells…
2015 American Transplant Congress
Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients
R. Villicana, A. Peng, J. Kahwaji, J. Choi, A. Vo, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Abatacept which is a co-stimulation inhibitor has been suggested to have B7-1 mediated antiproteinuric effects. Belatacept which is another co-stimulation agent has been approved…
2015 American Transplant Congress
Renal Allografts Demonstrate Improved Pathology After Belatacept Therapy
T. Saavedra,¹ O. Opara,¹ R. McLoughlin,¹ B. Philosophe,² C. Drachenberg,¹ M. Weir,¹ S. Bartlett,¹ D. Leeser,¹ J. Bromberg,¹ R. Barth.¹
¹University of Maryland School of Medicine, Baltimore; ²Johns Hopkins University, Baltimore.
Belatacept provides immunosuppression via costimulation blockade and has been associated with improved renal function compared to calcineurin inhibitor based therapies. We developed the Maryland Aggregate…
2015 American Transplant Congress
Virus Induced CD28 Down-Regulation as a Potential Driver of Costimulation Blockade Resistant Rejection
D. Mou,¹ J. Espinosa,¹ L. Stempora,² J. Kwun,² N. Iwakoshi,¹ A. Kirk.²
¹Surgery, Emory University, Atlanta, GA; ²Surgery, Duke University, Durham, NC.
Belatacept, a B7-specific fusion protein, blocks CD28-B7 costimulation and prevents kidney allograft rejection. However, it is ineffective in a sizable minority of patients. Although T…
2015 American Transplant Congress
Costimulation Blockade Prevents Rejection of Vascularized Composite Allografts
B. Oh,¹ G. Furtmüller,¹ M. Fryer,¹ J. Grahammer,² S. Schneeberger,² D. Cooney,¹ W. Lee,¹ G. Brandacher.¹
¹Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria.
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss. The…
2015 American Transplant Congress
Eomes-Expressing CD8+ T Cells and Th17 Cells Mediate Costimulatory Blockade-Resistant Allograft Rejection in Mice
M. Sabet-Baktach,¹ E. Eggenhofer,¹ P. Renner,¹ M. Lantow,¹ H. Schlitt,¹ E. Geissler,¹ A. Kroemer.^1,2
¹Department of Surgery, University Hospital Regensburg, Regensburg, Germany; ²Georgetown Transplant Institute, Georgetown Transplant Institute, Washington, DC.
The etiology of costimulatory blockade-resistant allograft rejection remains unclear. Therefore, the purpose of this study was to evaluate the responsiveness of distinct CD4+ and CD8+…
2015 American Transplant Congress
Tissue Engineering Human Kidneys for Costimulation Blockade
L. Brasile,¹ N. Henry,¹ A. Meyer,¹ B. Stubenitsky.²
¹BREONICS, Inc., Watervliet, NY; ²Surgery, University of Utrecht, Utrecht, Netherlands.
Methods for preserving organs have employed hypothermic conditions. At these temperatures metabolism is 4% of normal. Tissue engineering of organs cannot be done without significant…
2015 American Transplant Congress
Defining the Role of CD57+CD4 T Cells in Belatacept-Resistant Rejection
J. Espinosa,^1,2 L. Stempora,^1,2 R. Townsend,³ A. Kirk.^1,2
¹Duke University, Durham, NC; ²Emory University, Atlanta, GA; ³Bristol-Myers Squibb, Princeton, NJ.
Purpose: We have shown that CD57+PD1- CD4 T cells are present in higher numbers in the peripheral blood and allograft biopsies of patients who experienced…
2015 American Transplant Congress
Combined Anti-IL6R and CTLA4Ig Therapy Attenuates Recall Alloantibody Responses in a Mouse Model of HLA Sensitization
N.-N. Chai, G. Wu, I. Kim, A. Klein, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
[bald]Background[/bald] We previously reported that IL-6 inhibition by anti-IL6R antibody (mMR16-1) or CD28 pathway inhibition using CTLA4Ig (abatacept) reduced recall alloantibody responses in a mouse…